Meeting
2011 ASCO Annual Meeting
Phase II study of low-dose paclitaxel with timed thoracic radiotherapy (TTR) followed by gemcitabine and carboplatin consolidation in patients with unresectable stage III non-small cell lung cancer (NSCLC): NCT 00449657.
Authors
J. Zhang
Leo Jenkins Cancer Center, Brody School of Medicine at East Carolina University, Greenville, NC
J. Zhang , S. M. Russo , H. A. Gay , T. Parent , Z. Nelson , S. Eubanks , P. R. Walker
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer - Local-regional and Adjuvant Therapy/Small Cell
Track
Lung Cancer
Sub Track
Local-Regional Therapy
Clinical Trial Registration Number
NCT 00449657
Citation
J Clin Oncol 29: 2011 (suppl; abstr 7044)
Abstract #
7044
Poster Bd #
21H
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
Endostar in combination with radiotherapy and paclitaxel/carboplatin in patients with unresectable non-small cell lung cancer of stage III: Preliminary results of a phase II study.
First Author: S. Ma
Poster
2021 ASCO Annual Meeting
Randomized phase III Trial of MEDI4736 (durvalumab) as concurrent and consolidative therapy or consolidative therapy alone for unresectable stage 3 NSCLC: A trial of the ECOG-ACRIN Cancer Research Group (EA5181).
First Author: John M. Varlotto
Poster
2017 ASCO Annual Meeting
Randomized phase II trial of S-1 plus cisplatin or docetaxel plus cisplatin with concurrent thoracic radiotherapy for inoperable stage III non-small cell lung cancer (TORG1018).
First Author: Kaoru Kubota
Poster
2015 ASCO Annual Meeting
Comparison of concurrent use of carboplatin-Paclitaxel versus cisplatin-etoposide with thoracic radiation for stage III NSCLC patients: A systematic review.
First Author: Conor Ernst Steuer